These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12040355)

  • 1. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy.
    Tumlin JA; Wang A; Murray PT; Mathur VS
    Am Heart J; 2002 May; 143(5):894-903. PubMed ID: 12040355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
    Stone GW; McCullough PA; Tumlin JA; Lepor NE; Madyoon H; Murray P; Wang A; Chu AA; Schaer GL; Stevens M; Wilensky RL; O'Neill WW;
    JAMA; 2003 Nov; 290(17):2284-91. PubMed ID: 14600187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of CONTRAST--a prospective, randomized, placebo-controlled trial of fenoldopam mesylate for the prevention of radiocontrast nephropathy.
    Stone GW; Tumlin JA; Madyoon H; Lepor NE; McCullough PA; Mathur VS; Murray PT; O'Neill WW
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S31-6. PubMed ID: 12439366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing contrast-induced nephropathy with fenoldopam.
    Hunter DW; Chamsuddin A; Bjarnason H; Kowalik K
    Tech Vasc Interv Radiol; 2001 Mar; 4(1):53-6. PubMed ID: 11981789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial.
    Tumlin JA; Finkel KW; Murray PT; Samuels J; Cotsonis G; Shaw AD
    Am J Kidney Dis; 2005 Jul; 46(1):26-34. PubMed ID: 15983954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial.
    Morelli A; Ricci Z; Bellomo R; Ronco C; Rocco M; Conti G; De Gaetano A; Picchini U; Orecchioni A; Portieri M; Coluzzi F; Porzi P; Serio P; Bruno A; Pietropaoli P
    Crit Care Med; 2005 Nov; 33(11):2451-6. PubMed ID: 16276165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy.
    Kurnik BR; Allgren RL; Genter FC; Solomon RJ; Bates ER; Weisberg LS
    Am J Kidney Dis; 1998 Apr; 31(4):674-80. PubMed ID: 9531185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the high-risk patient: experience with fenoldopam, a selective dopamine receptor agonist, in prevention of radiocontrast nephropathy during percutaneous coronary intervention.
    Kini AA; Sharma SK
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S19-25. PubMed ID: 12439364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial.
    Bove T; Zangrillo A; Guarracino F; Alvaro G; Persi B; Maglioni E; Galdieri N; Comis M; Caramelli F; Pasero DC; Pala G; Renzini M; Conte M; Paternoster G; Martinez B; Pinelli F; Frontini M; Zucchetti MC; Pappalardo F; Amantea B; Camata A; Pisano A; Verdecchia C; Dal Checco E; Cariello C; Faita L; Baldassarri R; Scandroglio AM; Saleh O; Lembo R; Calabrò MG; Bellomo R; Landoni G
    JAMA; 2014 Dec; 312(21):2244-53. PubMed ID: 25265449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam.
    Kini AS; Mitre CA; Kim M; Kamran M; Reich D; Sharma SK
    Catheter Cardiovasc Interv; 2002 Feb; 55(2):169-73. PubMed ID: 11835641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy.
    Allaqaband S; Tumuluri R; Malik AM; Gupta A; Volkert P; Shalev Y; Bajwa TK
    Catheter Cardiovasc Interv; 2002 Nov; 57(3):279-83. PubMed ID: 12410497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients.
    Madyoon H; Croushore L; Weaver D; Mathur V
    Catheter Cardiovasc Interv; 2001 Jul; 53(3):341-5. PubMed ID: 11458411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prophylactic fenoldopam infusion on renal blood flow and renal tubular function during acute hypovolemia in anesthetized dogs.
    Halpenny M; Markos F; Snow HM; Duggan PF; Gaffney E; O'Connell DP; Shorten GD
    Crit Care Med; 2001 Apr; 29(4):855-60. PubMed ID: 11373482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy.
    Chamsuddin AA; Kowalik KJ; Bjarnason H; Dietz CA; Rosenberg MS; Gomes MD; McDermott CM; Hunter DW
    AJR Am J Roentgenol; 2002 Sep; 179(3):591-6. PubMed ID: 12185025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous hemodialysis during coronary angiography fails to prevent radiocontrast-induced nephropathy in chronic renal failure.
    Frank H; Werner D; Lorusso V; Klinghammer L; Daniel WG; Kunzendorf U; Ludwig J
    Clin Nephrol; 2003 Sep; 60(3):176-82. PubMed ID: 14524580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients.
    Brienza N; Malcangi V; Dalfino L; Trerotoli P; Guagliardi C; Bortone D; Faconda G; Ribezzi M; Ancona G; Bruno F; Fiore T
    Crit Care Med; 2006 Mar; 34(3):707-14. PubMed ID: 16505657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with the use of fenoldopam for prevention of radiocontrast nephropathy in high-risk patients.
    Madyoon H
    Rev Cardiovasc Med; 2001; 2 Suppl 1():S26-30. PubMed ID: 12439365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-Acetylcysteine versus fenoldopam mesylate to prevent contrast agent-associated nephrotoxicity.
    Briguori C; Colombo A; Airoldi F; Violante A; Castelli A; Balestrieri P; Paolo Elia P; Golia B; Lepore S; Riviezzo G; Scarpato P; Librera M; Focaccio A; Ricciardelli B
    J Am Coll Cardiol; 2004 Aug; 44(4):762-5. PubMed ID: 15312855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contrast-induced nephropathy: protective role of fenoldopam.
    Caixeta A; Dogan O; Weisz G
    Clin Exp Pharmacol Physiol; 2012 Jun; 39(6):497-505. PubMed ID: 22642656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenoldopam and renal function after partial nephrectomy in a solitary kidney: a randomized, blinded trial.
    O'Hara JF; Mahboobi R; Novak SM; Bonilla AM; Mascha EJ; Fergany AF; Campbell SC; Kaouk JH; Kaple KM; Gill IS; Ziegman SA; Sessler DI
    Urology; 2013 Feb; 81(2):340-5. PubMed ID: 23374797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.